Persistent and recurrent hyperparathyroidism

Current Treatment Options in Oncology

Volumn 5, Issue 4, 2004, Pages 335-345

  Caron, Nadine R ^b   Sturgeon, Cord ^b   Clark, Orlo H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALENDRONIC ACID; AMINOPHYLLINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCIUM; CATION; CINACALCET; CONJUGATED ESTROGEN; GESTAGEN; ISOTOPE; LIPOPROTEIN; LITHIUM; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; VITAMIN D;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE PHASE RESPONSE; ANATOMICAL VARIATION; BLOOD SAMPLING; BREAST CANCER; CATHETER ABLATION; COST EFFECTIVENESS ANALYSIS; CRYOPRESERVATION; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIET THERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISSECTION; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DYSPEPSIA; DYSPHAGIA; ECHOGRAPHY; EROSION; ESOPHAGITIS; ESOPHAGUS PERFORATION; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; EXPERIENCE; FEVER; FIBROSIS; GASTROESOPHAGEAL REFLUX; HAIR LOSS; HEADACHE; HEMATOMA; HORMONE DETERMINATION; HORNER SYNDROME; HUMAN; HYPOPARATHYROIDISM; IMPAIRED GLUCOSE TOLERANCE; INTRAOPERATIVE PERIOD; ISOTOPE LABELING; LARYNGEAL NERVE; LIFESTYLE; LIPOPROTEIN METABOLISM; MALAISE; MASTALGIA; MEDICAL EXPERT; METABOLIC DISORDER; MYALGIA; NAUSEA; NERVE PARALYSIS; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATHOLOGY; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIMARY HYPERPARATHYROIDISM; PRURITUS; RADIODIAGNOSIS; RECURRENT DISEASE; REOPERATION; REVIEW; RISK FACTOR; SAFETY; SCINTILLATION PROBE; SURGICAL APPROACH; THORAX PAIN; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; URTICARIA; UTERUS CANCER; VAGINA BLEEDING; VOMITING;

EID: 4344612216     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0024-4     Document Type: Review

References (49)

1. Clark OH: Symposium: parathyroid disease - part 1. Contemp Surg 1998, 52:137-152.
2. Mundschenk J, Klose S, Lorenz K, et al.: Diagnostic strategies and surgical procedures in persistent or recurrent primary hyperparathyroidism. Exp Clin Endocrinol Diabetes 1999, 107:331-336.
3. Wadstrom C, Zedenius L Guinea A, et al.: Re-operative surgery for recurrent or persistent primary hyperparathyroidism. Aust N Z J Surg 1998, 68:103-107.
4. Al-Fehaily M, Clark OH: Persistent or recurrent primary hyperparathyroidism. Ann Ital Chir 2003, 74:423-434.
5. Eigelberger MS, Cheah WK, Ituarte PH, et al.: The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited? Ann Surg 2004, 4:528-535.
6. Abdelhadi M, Nordenstrom J: Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 1998, 83:3845-3851.
7. Hedback G, Tisell LE, Bengtsson BA, et al.: Premature death in patients operated on for primary hyperparathyroidism. World J Surg 1990, 14:829-835.
8. Hedback G, Oden A: Increased risk of death from primary hyperparathyroidism: an update. Eur J Clin Invest 1998, 28:271-276.
9. Hedback G, Oden A: Death risk factor analysis in primary hyperparathyroidism. Eur J Clin Invest 1998, 28:1011-1118.
10. Palmer M, Adami HO, Bergstrom R, et al.: Survival and renal function in untreated hypercalcaemia: population-based cohort study with 14 years of follow-up. Lancet 1987, 1:59-62.
11. Mariette C, Pellissier L, Combemale F, et al.: Reoperation for persistent or recurrent primary hyperparathyroidism. Langenbecks Arch Surg 1998, 383:174-179.
12. Wells SA Jr, Debenedetti MK, Doherty GM: Recurrent or persistent hyperparathyroidism. J Bone Miner Res 2002, 17(Suppl 2):N158-N162.
13. Tezelman S, Shen W, Siperstein AE, et al.: Persistent or recurrent hyperparathyroidism in patients with double adenomas. Surgery 1995, 118:1115-1122.
14. Jaskowiak N, Norton JA, Alexander HR, et al.: A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma. Ann Surg 1996, 224:308-320.
15. Shen W, Duren M, Morita E, et al.: Reoperation for persistent or recurrent primary hyperparathyroidism. Arch Surg 1996, 131:861-867.
16. Kebebew E, Arici C, Duh QY, et al.: Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 2001, 136:878-885.
17. Alexander HR Jr, Chen CC, Shawker T, et al.: Role of preoperative localization and intraoperative localization maneuvers including intraoperative PTH assay determination for patients with persistent or recurrent hyperparathyroidism. J Bone Miner Res 2002, 17(Suppl 2):N133-N140.
18. Clark OH, Kaplan EL, Thompson NW, et al.: Symposium: parathyroid disease - part 2. Contemp Surg 1998, 52:213-224.
19. Gasparri G, Camandona M, Abbona GC, et al.: Secondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies. Ann Surg 2001, 233:65-69.
20. Udelsman R: Primary hyperparathyroidism. In Current Surgical Therapy. Edited by Cameron JL. St. Louis: Mosby; 2001:662-667.
21. Hubbard JG, Sebag F, Maweja S, et al.: Primary hyperparathyroidism in men 1: how radical should surgery be? Langenbecks Arch Surg 2002, 386:553-557.
22. Haciyanli M, Lal G, Morita E, et al.: Accuracy of preoperative localization studies and intraoperative parathyroid hormone assay in patients with primary hyperparathyroidism and double adenoma. J Am Coll Surg 2003, 197:739-746.
23. Kebebew E: Parathyroid carcinoma. Curr Treat Options Oncol 2001, 2:347-354.
24. Lentsch EJ, Withrow KP, Ackermann D, et al.: Parathyromatosis and recurrent hyperparathyroidism. Arch Otolaryngol Head Neck Surg 2003, 129:894-896.
25. Jones JJ, Brunaud L, Dowd CF, et al.: Accuracy of selective venous sampling for intact parathyroid hormone in difficult patients with recurrent or persistent hyperparathyroidism. Surgery 2002, 132:944-950.
26. Eigelberger MS, Clark OH: Surgical approaches to primary hyperparathyroidism. Endocrinol Metab Clin North Am 2000, 29:479-502.
27. Thompson GB, Grant CS, Perrier ND, et al.: Reoperative parathyroid surgery in the era of sestamibi scanning and intraoperative parathyroid hormone monitoring. Arch Surg 1999, 134:699-704.
28. Arici C, Cheah WK, Ituarte PH, et al.: Can localization studies be used to direct focused parathyroid operations? Surgery 2001, 129:720-729.
29. Miura D, Wada N, Arici C, et al.: Does intraoperative quick parathyroid hormone assay improve the results of parathyroidectomy? World J Surg 2002, 26:926-930.
30. Gotway MB, Reddy GP, Webb WR, et al.: Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent of persistent hyperparathyroidism. Radiology 2001, 218:783-790.
31. Cook GJ, Wong JC, Smellie WJ, et al.: [11C]Methionine positron emission tomography for patients with persistent or recurrent hyperparathyroidism after surgery. Eur J Endocrinol 1998, 139:195-197.
32. Bilezikian JP, Potts JT Jr, Fuleihan Gel H, et al.: Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002, 87:5353-5361.
33. Clark OH: How should patients with primary hyperparathyroidism be treated? J Clin Endocrinol Metab 2003, 88:3011-3014.
34. Dolan J, Norton JA: Surgery for persistent and recurrent primary hyperparathyroidism. In Surgical Endocrinology. Doherty GM, Skogseid B. Philadelphia: Lippincott Williams & Wilkins; 2001:173-188.
35. Hedback G, Oden A, Tisell LE: The influence of surgery on the risk of death in patients with primary hyperparathyroidism. World J Surg 1991, 15:399-405.
36. Asymptomatic primary hyperparathyroidism: standards and guidelines for diagnosis and management in Canada: Consensus development task force on diagnosis and management of asymptomatic primary hyperparathyroidism position paper. Endocr Pract 2003, 9:400-405.
37. Strewler GJ: Medical approaches to primary hyperparathyroidism. Endocrinol Metab Clin North Am 2000, 29:523-539.
38. Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
39. Zanchetta Jr, Bogado CE: Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res 2001, 16:189-190.
40. Quarles LD: Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues. Curr Opin Nephrol Hypertens 2003, 12:349-355.
41. Urena P, Frazao JM: Calcimimetic agents: review and perspectives. Kidney Int Suppl 2003:S91-S96.
42. Shoback DM, Bilezikian JP, Turner SA, et al.: The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88:5644-5649.
43. Cohen A, Silverberg SJ: Calcimimetics: therapeutic potential in hyperparathyroidism. Curr Opin Pharmacol 2002, 2:734-739.
44. Harman CR, Grant CS, Hay ID, et al.: Indications, technique, and efficacy of alcohol injection of enlarged parathyroid glands in patients with primary hyperparathyroidism. Surgery 1998, 124:1011-1019.
45. Bennedbaek FN, Karstrup S, Hegedus L: Percutaneous ethanol injection therapy in the treatment of thyroid and parathyroid diseases. Eur J Endocrinol 1997, 136:240-250.
46. Khafif A, Halperin D, Marshak G: Ethanol injection to parathyroid tissue: indications and limitations. Ear Nose Throat J 1998, 77:538-540.
47. Heller HJ, Miller GL, Erdman WA, et al.: Angiographic ablation of mediastinal parathyroid adenomas: local experience and review of the literature. Am J Med 1994, 97:529-534.
48. Howell P, Kariampuzha S, Kipgen W, et al.: Non-surgical therapy of primary hyperparathyroidism. J Okla State Med Assoc 2001, 94:561-565.
49. Pallotta JA, Sacks BA, Moller DE, et al.: Arteriographic ablation of cervical parathyroid adenomas. J Clin Endocrinol Metab 1989, 69:1249-1255.